J Pathol. 2008 Mar;214(4):498-507.

BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.

Perez-Rosado A, Artiga M, Vargiu P, Sanchez-Aguilera A, Alvarez-Barrientos A, Piris M.

Source

Lymphoma Group, Molecular Pathology Programme, Spanish National Cancer Centre (CNIO), Madrid, Spain.

Abstract

BCL6 is a transcriptional repressor whose deregulated expression plays a key role in diffuse large B-cell lymphomas (DLBCLs). BCL6 expression characterizes one of the two main subtypes (GC type) of DLBCL, while the other (ABC type) is recognized by increased NFkappaB activation. The mechanistic basis of this distinction remains unclear and the BCL6 targets have been only partially explored. Here we describe how NFkappaB activity is increased after BCL6 silencing by shRNA in DLBCL cells, leading us to propose that BCL6 represses NFkappaB activity. We also demonstrate that this repression is brought about by a mechanism involving protein-protein interaction between BCL6 and NFkappaB members, both in vitro and in vivo. Analysis of a series of DLBCLs shows a negative correlation between the expression of NFkappaB target genes and BCL6. This combined approach using silenced cells and a series of human DLBCL samples leads us to a better understanding of the role of BCL6 as an NFkappaB regulator in B-cells.

PMID:: 18189332; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Lymphoma - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. [Blood. 2009]
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN, Ye K, Farinha P, Horsman DE, Gascoyne RD, et al. Blood. 2009 May 28; 113(22):5536-48. Epub 2009 Mar 23.
NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. [Blood. 2005]
NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.
Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL, et al. Blood. 2005 Aug 15; 106(4):1392-9. Epub 2005 May 3.
Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. [Blood. 2003]
Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R. Blood. 2003 Apr 15; 101(8):2914-23. Epub 2002 Dec 19.
Review BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. [Adv Immunol. 2010]
Review BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis.
Basso K, Dalla-Favera R. Adv Immunol. 2010; 105:193-210.
Review Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. [Leuk Lymphoma. 2008]
Review Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.
Parekh S, Privé G, Melnick A. Leuk Lymphoma. 2008 May; 49(5):874-82.

See reviews... See all...

Cited by 4 PubMed Central articles

Male-Dominant Activation of Rat Renal Organic Anion Transporter 1 (Oat1) and 3 (Oat3) Expression by Transcription Factor BCL6. [PLoS One. 2012]
Male-Dominant Activation of Rat Renal Organic Anion Transporter 1 (Oat1) and 3 (Oat3) Expression by Transcription Factor BCL6.
Wegner W, Burckhardt BC, Burckhardt G, Henjakovic M. PLoS One. 2012; 7(4):e35556. Epub 2012 Apr 18.
Bcl-6 and NF-kappaB cistromes mediate opposing regulation of the innate immune response. [Genes Dev. 2010]
Bcl-6 and NF-kappaB cistromes mediate opposing regulation of the innate immune response.
Barish GD, Yu RT, Karunasiri M, Ocampo CB, Dixon J, Benner C, Dent AL, Tangirala RK, Evans RM. Genes Dev. 2010 Dec 15; 24(24):2760-5. Epub 2010 Nov 24.
Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma. [Int J Clin Exp Med. 2010]
Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.
De J, Brown RE. Int J Clin Exp Med. 2010 Jan 30; 3(1):55-68. Epub 2010 Jan 30.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
J Pathol. 2008 Mar ;214(4):498-507.

PubMed
Geographic access to cancer care in the U.S.
Geographic access to cancer care in the U.S.
Cancer. 2008 Feb 15 ;112(4):909-18.

PubMed
The role of human epidermal growth factor receptor 2 in the survival of women wi...
The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
Cancer. 2008 Feb 15 ;112(4):737-47.

PubMed
Using peptides to study the interaction between the p53 tetramerization domain a...
Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat.
Biopolymers. 2008 ;90(2):105-16.

PubMed
No evidence for involvement of genetic variants in the X-linked neuroligin genes...
No evidence for involvement of genetic variants in the X-linked neuroligin genes NLGN3 and NLGN4X in probands with autism spectrum disorder on high functioning level.
Am J Med Genet B Neuropsychiatr Genet. 2008 Jun 5 ;147B(4):535-7.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: